5 papers about lung cancer suggested by Stephen Liu

Stephen Liu, Head of Developmental Therapeutics at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers on X:

Final analysis data and exploratory biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFRmutations: the WJOG9717L study

Authors: Hirotsugu Kenmotsu et al.

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)

Authors: Kageaki Watanabe et al.

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Authors: James Chih-Hsin Yang et al.

Brief Report: Impact of Maintenance Pemetrexed Cessation on Clinical Outcomes of Patients with Metastatic Non-Squamous NSCLC

Authors: Shreya Bhatia, Matthew Lu, Spencer Lessans, Michael Libre, Heidi Chen, Wade Iams

Capmatinib efficacy for METex14 non-small cell lung cancer patients: Results of the IFCT-2104 CAPMATU study

Authors: Marion Ferreira et al.

Follow Stephen Liu on X for more such content.

Stephen Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.

As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.

Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.